M&A - BISCHOFBERGER NORBERT W

Form Type: SCHEDULE 13D/A

Filing Date: 2025-06-20

Corporate Action: Merger

Type: Update

Accession Number: 000114036125023175

Filing Summary: On June 20, 2025, the Issuer, Kronos Bio, Inc., completed a merger with Concentra Biosciences, LLC, resulting in Kronos becoming a wholly-owned subsidiary of Concentra. Each outstanding share of Kronos' common stock was converted into $0.57 in cash and one contractual contingent value right. The Reporting Persons, including Norbert Bischofberger, Ph.D., ceased to hold beneficial ownership of any shares of Kronos' common stock after the merger. This Schedule 13D/A amendment reports this change, following the prior filings regarding the beneficial ownership. Furthermore, all stock options held were converted into cash consideration as part of the merger transactions, and the Reporting Persons have not conducted any transactions in the common stock within the 60 days preceding the merger closure.